



## 24 **Abstract**

25 COVID-19 has affected more than half a billion people worldwide, with  
26 more than 6.3 million deaths, but the pathophysiological mechanisms involved  
27 in lethal cases and the host determinants that determine the different clinical  
28 outcomes are still unclear. In this study, we assessed lung autopsies of 47  
29 COVID-19 patients and examined the inflammatory profiles, viral loads, and  
30 inflammasome activation. Additionally, we correlated these factors with the  
31 patient's clinical and histopathological conditions. Robust inflammasome  
32 activation, mediated by macrophages and endothelial cells, was detected in the  
33 lungs of lethal cases of SARS-CoV-2. An analysis of gene expression allowed  
34 for the classification of COVID-19 patients into two different clusters. Cluster 1  
35 died with higher viral loads and exhibited a reduced inflammatory profile than  
36 Cluster 2. Illness time, mechanical ventilation time, pulmonary fibrosis,  
37 respiratory functions, histopathological status, thrombosis, viral loads and  
38 inflammasome activation significantly differed between the two clusters. Our  
39 data demonstrated two distinct profiles in lethal cases of COVID-19, thus  
40 indicating that the balance of viral replication and inflammasome-mediated  
41 pulmonary inflammation led to different clinical outcomes. We provide important  
42 information to understand clinical variations in severe COVID-19, a process that  
43 is critical for decisions between immune-mediated or antiviral-mediated  
44 therapies for the treatment of critical cases of COVID-19.

45

## 46 Introduction

47

48 After the COVID-19 pandemic, coronaviruses became frequent viral agents of  
49 acute respiratory distress syndrome (ARDS). Between 2019 and 2021, there  
50 were more than 255,000,000 confirmed cases and 5,127,000 deaths caused by  
51 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide  
52 (WHO, 2020). Severe ARDS is characterized by major pulmonary involvement,  
53 respiratory distress, systemic thrombosis, and death (Batah and Fabro, 2021;  
54 Bösmüller et al., 2021; Polak et al., 2020). The activation of the NLRP3  
55 inflammasome has been described in response to SARS-CoV-2 infections  
56 (Cama et al., 2021; Einfeld et al., 2021; Junqueira et al., 2022; Lucas, 2020;  
57 Rodrigues et al., 2021; Sefik et al., 2022), and this process contributes to  
58 excessive inflammation and poor clinical outcome. The recruitment of immune  
59 cells to the lungs of infected individuals culminates in the excessive release of  
60 cytokines that cause structural damage to the lungs (Kommos et al., 2020; Xu  
61 et al., 2020). Moreover, the major reported lung pathologies of severe COVID-  
62 19 include diffuse alveolar damage (DAD), acute fibrinoid organizing pneumonia  
63 (AFOP), and chronic interstitial pneumonia (Batah and Fabro, 2021; Bösmüller  
64 et al., 2021; Polak et al., 2020; Sauter et al., 2020). NLRP3 inflammasome  
65 activation also occurs in the lung parenchyma of these patients (Rodrigues et  
66 al., 2021; Toldo et al., 2021). However, it is still unknown how inflammasome  
67 activation promotes the exacerbated inflammatory process during SARS-CoV-2  
68 infection and how it impacts viral replication and the development of important  
69 clinical characteristics associated with death in COVID-19 patients. In the  
70 present study, postmortem lung tissue samples from 47 fatal COVID-19 patients  
71 were examined for inflammasome activation and gene expression; in addition,  
72 these factors were correlated with the clinical conditions of the patients to  
73 understand the molecular mechanisms underlying the pathological processes  
74 that lead to the death of these patients. We demonstrated the presence of  
75 robust inflammasome activation in the lungs of patients infected with SARS-  
76 CoV-2 and defined the specific cell types that contribute most to inflammasome  
77 activation. An analysis of gene expression in pulmonary tissues allowed for the  
78 classification of COVID-19 patients into two different clusters: one cluster with

79 patients who died with higher viral loads and reduced inflammatory profiles,  
80 which opposes the data from the other cluster. Our data establish that the  
81 magnitude of inflammasome activation contributes to the pathology of COVID-  
82 19 by balancing a thrombotic versus a fibrotic process that impacts the clinical  
83 outcome of the disease and patient death.

84

## 85 **Results**

86

### 87 ***Lethal cases of COVID-19 develop severe acute respiratory distress*** 88 ***syndrome (ARDS) and higher inflammasome activation.***

89

90 We evaluated inflammasome activation in the lung parenchyma of 47 patients  
91 who died from SARS-CoV-2 infection from April to July 2020. These patients  
92 were infected with the ancestral strain of SARS-CoV-2 before the development  
93 of the COVID-19 variants of concern and before the use of vaccinations. As  
94 noninfected controls, we evaluated inflammasome activation in biopsies of the  
95 benign area of the lungs from patients who died due to lung adenocarcinoma  
96 (referred as uninfected controls). The data in **Table 1** show the demographic  
97 and clinical characteristics of the 47 patients. As reported in the early COVID-19  
98 cases (that occurred in 2020), we found a high frequency of comorbidities, such  
99 as hypertension, obesity, diabetes, heart and lung disease. Furthermore, the  
100 patients exhibited altered values of CRP, D-dimers, LDH, creatinine, urea, AST,  
101 ALT, PT (INR), and blood glucose levels. The patients had an average illness  
102 time of 18 days, and the majority of the patients (76.59%) used MV, with an  
103 average of 12.38 days of use of mechanical ventilation. The patients had  
104 considerably altered PaO<sub>2</sub> and PaO<sub>2</sub>/FiO<sub>2</sub> characterizing a moderate to severe  
105 ARDS condition and consistent with the respiratory statuses. The  
106 histopathological analyses of COVID-19 patients demonstrated a high fibrotic  
107 phase of DAD, OP, and pneumonitis (**Table 1**). To analyze the histological  
108 features of patients' lungs, we measured the lung parenchyma area in the  
109 histological sections to assess loss of airspace. In support of the data described  
110 above, we observed that COVID-19 patients had a higher parenchyma area



111 (loss of airspace), suggesting that SARS-CoV-2 triggers robust inflammatory  
112 infiltration to the lung in severe cases of the disease (**Supplementary Fig. 1A-**  
113 **C**). These data are in agreement with histopathological findings showing an  
114 intense inflammatory process in patients who died from SARS-CoV-2 (Batah  
115 and Fabro, 2021; Hariri et al., 2021). To assess inflammasome activation in the  
116 lungs of COVID-19 patients, the lung parenchyma area and cell count were  
117 scanned in histological sections by using multiphoton microscopy. The  
118 parenchyma area was calculated by using ImageJ software, and inflammasome  
119 activation was microscopically scored by the presence of characteristic NLRP3  
120 or ASC puncta/specks (Hauenstein et al., 2015). The parenchyma area was  
121 used to normalize all of the counts between the patients. Inflammasome  
122 activation was quantified by counting ASC and NLRP3 puncta in the lung tissue  
123 of these patients. We observed that patients with SARS-CoV-2 infection had  
124 robust inflammasome activation, as shown by the abundant presence of ASC  
125 and NLRP3 puncta in the lungs (**Supplementary Fig. 1D-G**). Representative  
126 images of ASC and NLRP3 puncta in the patients' lungs are shown  
127 (**Supplementary Fig. 1E, G**). Importantly, we observed ASC colocalization in  
128 nearly all of the scored NLRP3 puncta, thus confirming that these puncta  
129 structures that were abundantly found in the patient's lungs are indeed the  
130 NLRP3/ASC inflammasome (**Supplementary Fig. 1H, I**). Collectively, these  
131 data indicate that COVID-19 patients have high inflammasome activation and  
132 that these patients evolved to a fibrotic phase of DAD, OP, and pneumonitis.

133

### 134 ***Macrophages and endothelial cells contribute to inflammasome activation*** 135 ***in lethal cases of COVID-19.***

136

137 To comprehensively investigate the cell types operating during SARS-CoV-2  
138 infection, we aimed to assess which cell types promote inflammasome  
139 activation in the lung of COVID-19 patients. We found abundant ASC and  
140 NLRP3 puncta in macrophages (CD64<sup>+</sup>), endothelial cells (CD34<sup>+</sup>), type 1  
141 pneumocytes (PDPN<sup>+</sup>), and type 2 pneumocytes (SFTPC<sup>+</sup>) (**Figure 1A-H**). We  
142 scored ASC and NLRP3 puncta in CD64<sup>+</sup>, CD34<sup>+</sup>, PDPN<sup>+</sup>, and SFTPC<sup>+</sup> and  
143 compared them with uninfected controls. We observed that in the lungs of

144 COVID-19 patients, both ASC and NLRP3 puncta were significantly higher in  
145 macrophages (**Figure 1I, M**) and endothelial cells (**Figure 1J, N**) than in  
146 controls. In contrast, in the assessment of type 1 and type 2 pneumocytes, we  
147 found that ASC and NLRP3 puncta did not differ from uninfected controls,  
148 suggesting that these cells contribute less to overall inflammasome activation  
149 (**Figure 1K, L, O, P**). Analyzing the total numbers of macrophages, endothelial  
150 cells, type 1 pneumocytes, and type 2 pneumocytes in the lungs of patients who  
151 died from SARS-CoV-2 infection, we did not find differences in total counts of  
152 these cell types comparing COVID-19 and uninfected controls (**Supplementary**  
153 **Fig. 2A-D**). Together, these data demonstrate the main contribution of  
154 macrophages and endothelial cells but not pneumocytes, to inflammasome  
155 activation during SARS-CoV-2 infection.

156

157 Subsequently, we performed immunohistochemistry analyses of the lung  
158 parenchyma to assess the expression of inflammasome components and  
159 observed variable expression of NLRP3, ASC, cleaved GSDMD, IL-1 $\beta$ , and  
160 caspase-1 in COVID-19 patients (**Supplementary Fig. 3A-E**). To assess which  
161 lung parenchyma cells expressed these inflammasome components, we used  
162 immunohistochemistry to evaluate the expression of ASC, NLRP3, caspase-1,  
163 cleaved GSDMD, and IL-1 $\beta$  on macrophages, endothelial cells, and type 2  
164 pneumocytes. We also stained these tissues with anti-Spike of SARS-CoV-2  
165 and found that virus-associated endothelial cells, macrophages, and type 2  
166 pneumocytes expressed ASC, NLRP3, Caspase-1, and IL-1 $\beta$  (**Supplementary**  
167 **Fig. 3F-H**).

168

169 ***Disease progression in fatal cases of COVID-19 occurs with decreasing***  
170 ***viral load and increasing inflammasome activation.***

171

172 To assess whether inflammasome activation was associated with specific  
173 patient clinical conditions, we performed Pearson's correlations in COVID-19  
174 patients. Even though all of these patients died, we observed a strong negative  
175 correlation between viral load and the time of the disease (symptoms onset to

176 death) (**Figure 2A, B**). In addition, we observed a positive correlation between  
177 the amount of NLRP3 and ASC puncta with the time of disease (**Figure 2C, D**),  
178 thus suggesting that, in general, whereas the viral load is reduced,  
179 inflammasome activation increases during hospitalization in these lethal cases  
180 of COVID-19. We also observed significant negative correlations between  
181 NLRP3 puncta and PaO<sub>2</sub>/FiO<sub>2</sub> (**Figure 2E**), suggesting that inflammasome  
182 activation is related to an overall worsening pulmonary function. We detected no  
183 statistically significant correlations between NLRP3 or ASC puncta and viral  
184 load in the tissues (**Supplementary Fig. 4**).

185

### 186 **Inflammasome activation and pulmonary viral loads define two distinct** 187 **clinical outcomes in lethal cases of COVID-19.**

188

189 The imbalance of inflammatory and anti-inflammatory processes leads to an  
190 excessive release of cytokines into the systemic circulation with potentially  
191 deleterious consequences, including systemic inflammatory response syndrome  
192 (SIRS), circulatory shock, multiorgan dysfunction syndrome (MODS), and death  
193 (Sinha et al., 2020). Several studies have reported the association of SARS-  
194 CoV-2 with hyperinflammatory syndrome related to disease severity (Chen et  
195 al., 2021; Huang et al., 2005; Qin et al., 2020), and inflammasome activation  
196 may be associated with Cytokine Release Syndrome (CRS) (Cui and Zhang,  
197 2020; Dolinay et al., 2012; Olajide et al., 2021). Thus, to correlate  
198 inflammasome activation with the hyperinflammatory profile observed in lethal  
199 cases of COVID-19, we analyzed the expression of genes related to the  
200 inflammatory process and inflammasome activation. We evaluated gene  
201 expression in the lungs of COVID-19 patients and observed that several  
202 inflammatory cytokine genes positively correlate with genes involved in  
203 inflammasome activation (**Supplementary Fig. 5A**). We did not observe a  
204 significant difference in the expression of these genes when we compared  
205 COVID-19 patients with uninfected controls (**Supplementary Fig. 5B-U**),  
206 possibly due to the large dispersion of data observed in COVID-19 patients.  
207 Due to this dispersion and high variation in gene expression detected in COVID-  
208 19 patients, we performed an unsupervised heatmap constructed with data from

209 relative gene expression and revealed the formation of two clusters in COVID-  
210 19 patients (**Figure 3**). Cluster 1 was characterized by a higher viral load and  
211 lower expression of inflammasome and inflammatory genes. In contrast to  
212 Cluster 1, Cluster 2 was comprised of patients who died with a lower viral load  
213 and increased expression of inflammasome and inflammatory genes (**Figure**  
214 **3A**). To gain insights into key differences between these two clusters, we  
215 analyzed PaO<sub>2</sub>/FiO<sub>2</sub> and A-a O<sub>2</sub> gradient kinetics in these patients. We  
216 observed that patients in Cluster 2, who had overall increased inflammation,  
217 had worsening pulmonary function compared to those in Cluster 1 (**Figure 3B,**  
218 **C**). Basic demographic information stratified by cluster is provided in **Table 2**.  
219 Strikingly, patients who belonged to Cluster 2 had a long illness time (**Figure**  
220 **3D**), worse pulmonary function (as indicated by the PaO<sub>2</sub>/FiO<sub>2</sub> and A-a O<sub>2</sub>  
221 gradients) (**Figure 3E, F**), greater inflammasome activation, as measured by  
222 NLRP3 puncta formation (**Figure 3G**), and increased area of pulmonary  
223 parenchyma, indicating loss of airways (**Figure 3H**). Images of the lung  
224 parenchyma of three representative patients from each cluster are shown  
225 (**Figure 3I-J**). Importantly, we found that patients belonging to Cluster 2 had an  
226 overall lower viral load than patients from Cluster 1; this was quantified both by  
227 RT-PCR for N2 and E gene expression (**Figure 4A, B**), and by expression of  
228 Spike protein (**Figure 4C-E**). Next, we assessed radiological analyses of 15  
229 patients from Cluster 1 and 31 patients from Cluster 2 by comparing the first  
230 and last chest X-ray images (CXR) and observed overall worsening pulmonary  
231 conditions in patients from Cluster 2 (**Supplementary Fig. 6A**). Representative  
232 images of CXR of two patients from Cluster 1, with Mild/Moderate pneumonia  
233 (stable conditions) (**Supplementary Fig. 6B**) and two patients from Cluster 2  
234 with severe pneumonia (worsening) are shown (**Supplementary Fig. 6C**).  
235 **Table 3** summarizes the general imaging evaluation findings for the patients in  
236 Cluster 1 and Cluster 2. Taken together, our data suggest the existence of two  
237 distinct groups of patients who succumbed to COVID-19, one group with lower  
238 viral loads, higher inflammation, and worse pulmonary conditions than the other  
239 group.

240

241 **Differential regulation of fibrinolysis-related genes and growth factors**  
242 **dictate the induction of fibrosis or disseminated intravascular coagulation**  
243 **in fatal cases of COVID-19.**

244

245 Histopathological analyses of the lungs from lethal cases of COVID-19  
246 belonging to Clusters 1 and 2 allowed us to detect an increased development of  
247 fibrosis in patients from Cluster 2 (**Figure 5A, and Table 2**). By contrast,  
248 patients belonging to Cluster 1 exhibited a markedly increased disseminated  
249 intravascular coagulation (**Figure 5B, and Table 2**), according to the  
250 parameters recommended by the International Society of Thrombosis and  
251 Hemostasis (ISTH) (Taylor et al., 2001). In support of our analyses  
252 demonstrating increased disseminated intravascular coagulation, we found  
253 reduced platelet counts in patients from Cluster 1 (**Figure 5C, and Table 2**),  
254 supporting that vascular dysfunctions impact clinical outcomes in patients  
255 belonging to Cluster 1.

256

257 To further investigate the biological pathways involved in the induction of  
258 fibrosis in Cluster 2 patients, we assessed the expression of fibrosis-related  
259 genes in the patient's lungs. We observed an increased expression of genes  
260 related to fibrinolysis, inflammatory cytokines, nitric oxide-induced, extracellular  
261 matrix deposition, and extracellular matrix remodeling in patients belonging to  
262 Cluster 2 (**Figure 5D**). A volcano plot indicates genes differentially expressed in  
263 samples from Cluster 2 compared to Cluster 1, including *Plg* (**Figure 5E**), *Plat*  
264 (**Figure 5F**), *Plau* (**Figure 5G**); *Ccr2* (**Figure 5H**), *Ccl3* (**Figure 5I**); *Cdkna1*  
265 (**Figure 5J**); *Serpina1* (**Figure 5K**), *Timp2* (**Figure 5L**) and *Fgf1* (**Figure 5M**).  
266 To further illustrate the differences between fibrosis and thrombosis in patients  
267 from these different clusters, we performed Masson-Goldner staining to assess  
268 erythrocytes and clot formation (bright red) and collagen deposition (green) in  
269 Patients' lungs. By assessing three patients from each cluster, we found an  
270 increased collagen deposition in Cluster 2 patients, suggesting an increased  
271 fibrotic process (**Figure 5N**). By contrast, samples from Cluster 1 show  
272 increased clot formation, suggesting increased thrombotic processes (**Figure**  
273 **5O**). Together, these data support the hypothesis that fatal cases of COVID-19

274 progress via induction of disseminated intravascular coagulation, culminating in  
275 a thrombotic process or via a fibrotic process, which is aggravated by the  
276 inflammasome-induced exacerbated inflammation.

277

## 278 **Discussion**

279

280 COVID-19 is significantly lethal in nonvaccinated individuals, and although  
281 inflammation and cytokine storm are associated with poor clinical outcomes, the  
282 mechanisms underlying dysregulated inflammatory processes are unknown.  
283 The revelation that exacerbated inflammasome activation contributes to COVID-  
284 19 pathology (Junqueira et al., 2022; Rodrigues et al., 2021; Sefik et al., 2022)  
285 advanced the understanding of disease pathology, but a significant proportion  
286 of the lethal cases progresses with lower inflammasome activation. Our analysis  
287 of 47 fatal COVID-19 cases allowed for the classification of the patients into two  
288 groups. Cluster 2 showed a remarkably high inflammasome activation and  
289 hyperexpression of inflammatory genes with increased pulmonary fibrosis and  
290 worsened respiratory functions. By contrast, patients belonging to Cluster 1 died  
291 faster, with higher viral loads, reduced inflammatory process, and increased  
292 disseminated intracellular coagulation. Our data reveal two distinct profiles in  
293 lethal cases of COVID-19, thus indicating that the balance of viral replication  
294 and inflammasome-mediated pulmonary inflammation led to different clinical  
295 outcomes.

296

297 Patients belonging to Cluster 2, died of poor respiratory functions and increased  
298 fibrosis induced by the excessive inflammatory process. Inflammatory cytokines  
299 released upon inflammasome activation have been previously linked to the  
300 development of pulmonary fibrosis (Cho et al., 2020; Hussain et al., 2014; Lv et  
301 al., 2018; Meng et al., 2015; Meng et al., 2019; Sun et al., 2016). In addition,  
302 cytokines such as IL-1 $\beta$ , IL-18, and IL-1 $\alpha$  have been described as triggering the  
303 activation of fibroblasts and stimulating the synthesis and accumulation of type I  
304 collagen, TIMP, collagenase, and PGE2 (Hussain et al., 2014; Postlethwaite et  
305 al., 1988), which may contribute to the triggering of the deleterious effects of  
306 inflammasomes in patients' lungs. Interestingly, patients from Cluster 2 died



307 with low viral loads and higher inflammasome activation; in many patients from  
308 this cluster, viral loads were not detected, suggesting that SARS-CoV-2 per se  
309 may not be required for continuous inflammasome activation in the lungs of  
310 these patients. How NLRP3 inflammasome is activated in the tissues is still  
311 unknown, it is possible that Damage-Associated Molecular Patterns (DAMPs)  
312 participate in this process. Alternatively, it is possible that viral proteins  
313 produced before viral elimination or undetectable levels of SARS-CoV-2 present  
314 in the tissues are sufficient to activate NLRP3 inflammasome. Future studies  
315 will be required to clarify these questions. We also tested whether the  
316 mechanical ventilation used in COVID-19 patients would interfere with  
317 inflammasome activation. This hypothesis is supported by data indicating that  
318 mechanical ventilation-induced hyperoxia can induce potassium efflux through  
319 the P<sub>2</sub>X<sub>7</sub> receptor, thus leading to inflammasome activation and the secretion of  
320 proinflammatory cytokines (Dolinay et al., 2012; Jones et al., 2014; Kolliputi et  
321 al., 2010; Kuipers et al., 2012; Wu et al., 2013; Zhang et al., 2014). This does  
322 not appear to be the case in our study, as when we separated the COVID-19  
323 patients into two groups according to the use or non-use of mechanical  
324 ventilation, we detected no differences in histopathological analyses and  
325 inflammasome activation (**Table 4**). Moreover, we confirmed that patients who  
326 underwent mechanical ventilation had a longer illness time, higher  
327 hypertension, less CRP and albumin, higher amounts of urea, and worsened  
328 pulmonary function (according to the PaO<sub>2</sub>/FiO<sub>2</sub> and A-a O<sub>2</sub> gradients). Thus,  
329 our data do not support the hypothesis that mechanical ventilation is directly  
330 associated with inflammasome activation.

331

332 The mechanisms underlying dysregulated inflammatory processes and the cell  
333 types involved in inflammasome activation in COVID-19 are largely unknown.  
334 Macrophages are possibly the most effective cell types that trigger  
335 inflammasome activation (Broz and Dixit, 2016); according to this information,  
336 our data showed that macrophages in the lungs of COVID-19 patients are  
337 effectively infected and strongly induce inflammasome activation. These data  
338 are in agreement with previously published articles indicating high levels of viral  
339 RNA in lung monocytes and macrophages of COVID-19 patients (Delorey et al.,

2021; Pontelli et al., 2022), as well as pronounced inflammasome activation in  
macrophages from COVID-19 patients (Junqueira et al., 2022; Rodrigues et al.,  
2021; Sefik et al., 2022). In addition to inflammasome activation in  
macrophages, the analysis of inflammasome activation in different pulmonary  
cell types indicates that endothelial cells exposed to SARS-CoV-2 express  
inflammasome proteins and contain active NLRP3/ASC puncta, thus  
demonstrating inflammasome activation. Despite reports indicating that  
endothelial cells are not productively infected by SARS-CoV-2 (Schimmel et al.,  
2021), precursors of hematopoietic and endothelial cells stimulated with SARS-  
CoV-2 spike protein increase the expression of *AIM2*, *NLRP1*, *NLRP3*, *IL1B*,  
and *ASC* and trigger caspase-1 activation (Kucia et al., 2021; Ratajczak et al.,  
2021). In addition, inflammasome activation in endothelial cells has been  
previously reported (Paul et al., 2021; Xiang et al., 2011; Xu et al., 2013; Yang  
et al., 2016). These observations are consistent with our data indicating the  
expression of inflammasome components and inflammasome activation in  
CD34+ cells in the lungs of COVID-19 patients. Although these cells were  
stained positive for the SARS-CoV-2 spike protein, it is unknown whether  
infection and viral replication are required for inflammasome activation in these  
cells. It is possible that exosomes, released from COVID-19-infected cells,  
trigger NLRP3 inflammasome in endothelial cells (Sur et al., 2022).  
Alternatively, It is possible that spike stimulation is sufficient for inflammasome  
activation, which is a feature that would explain reports indicating damage and  
dysfunction of these cells during COVID-19 and the characterization of COVID-  
19 as an endothelial disease (Hottz et al., 2020; Libby and Lüscher, 2020; Liu et  
al., 2021; Nuovo et al., 2021; Varga et al., 2020; Ward et al., 2021). Importantly,  
vascular endothelium is actively involved in the regulation of inflammation and  
thrombus formation. This is particularly important in COVID-19 because the  
interplay between inflammasome activation in macrophages and the  
endothelium can lead to pyroptotic macrophages releasing tissue factor (TF),  
which is an essential initiator of coagulation cascades that are frequently  
observed in severe cases of COVID-19 (Campos et al., 2021; Wu et al., 2019;  
Zhang et al., 2021). These data support the association of inflammasomes with  
the coagulopathy that is observed in COVID-19.



373 In this study, we demonstrated specific cell types involved in inflammasome  
374 activation in patients' lungs and identified two distinct profiles in lethal cases of  
375 COVID-19. The revealed balance of viral-induced intravascular coagulation  
376 versus inflammasome-mediated pulmonary inflammation contributes to our  
377 understanding of disease pathophysiology and may contribute to decisions  
378 between immune-mediated or antiviral-mediated therapies for the treatment of  
379 critical cases of COVID-19.

380

## 381 **Methods**

382

### 383 ***Samples and Study Approval***

384 Minimally invasive autopsy was performed on 47 patients diagnosed with  
385 SARS-CoV-2 at the Hospital das Clínicas da Faculdade de Medicina de  
386 Ribeirão Preto da Universidade de São Paulo, Brazil (Ribeirão Preto, SP,  
387 Brazil) from April to July, 2020, by Serviço de Patologia (SERPAT). Minimally  
388 invasive autopsy was done at bedside through post-mort surgical lung biopsy by  
389 a matching 14-gauge cutting needle (Magnum Needles, Bard) and a biopsy gun  
390 (Magnum, Bard). Moreover, a 3 cm incision on the more affected side of the  
391 chest between the fourth and fifth ribs were also used to provide extra lung  
392 tissue. All tissue samples were embedded in paraffin and fixed in formalin  
393 (Formalin-Fixed Paraffin- Embedded, FFPE). Lung tissue from biopsy of Lung  
394 Adenocarcinoma patients (n=5) were obtained from SERPAT. The project was  
395 approved by the Research Ethics Committee of FMRP/USP under protocol n<sup>o</sup>  
396 4,089.567.

397

### 398 ***Immunohistochemistry (IHC)***

399 Tissue section in paraffin blocks were tested by immunohistochemistry using  
400 antibodies for the detection of NLRP3 (clone D2P5E; 1:3,000; Cell Signaling),  
401 ASC (1:2,000; Adipogen AL177), SFTPC (1:200, ThermoFisher PA5-71680),  
402 CD68 (1:200, Dako M0814), CD34 (1:500, Zeta Z2063ML), PDPN (1:200,  
403 ThermoFisher 14-9381-82), Anti-cleaved N-terminal GSDMD (1:200, Abcam

404 ab215203), Caspase-1 (1:200, Abcam ab207802), IL-1 $\beta$  (1:200, Abcam  
405 ab2105) for the *in situ* detection of these inflammasome proteins. The  
406 Sequential Immunoperoxidase Labeling and Erasing (SIMPLE) technique was  
407 used to evaluate all markers in the same tissue, as previously published (Glass  
408 et al., 2009). Briefly, after incubation with primary antibody (overnight at 4°C),  
409 slides were incubated with immune peroxidase polymer anti-mouse  
410 visualization system (SPD-125, Spring Bioscience, 345 Biogen) and with  
411 chromogen-substrate AEC peroxidase system kit (SK-4200, 346 Vector  
412 Laboratories, Burlingame, CA). After high resolution scanning by a VS120  
413 Olympus microscope, the coverslips were removed in PBS and the slides were  
414 dehydrated in an ethanol gradient to 95% ethanol. The slides were incubated in  
415 a series of ethanol to erase the AEC marking. Afterwards the slides were  
416 rehydrated and the antibodies were removed with an incubation for 2 min in a  
417 solution of 0.15 mM 351 KMnO<sub>4</sub>/0.01 M H<sub>2</sub>SO<sub>4</sub>, followed immediately by a  
418 wash in distilled water. Tissues were then remarked.

419

#### 420 ***Immunofluorescence***

421 The slides were incubated with the primary antibodies, rabbit anti-human  
422 NLRP3 mAb (clone D2P5E; 1:300; Cell Signaling), rabbit anti-human ASC  
423 polyclonal antibody (1:200; Adipogen AL177), SFTPC (1:200, ThermoFisher  
424 PA5-71680), CD64 (1:200, Biolegend 139304), CD34 (1:500, Zeta Z2063ML),  
425 PDPN (1:200, ThermoFisher 14-9381-82), overnight at 4°C and with the  
426 secondary antibodies Goat anti-mouse Alexa fluor-647 (Invitrogen) or Goat anti-  
427 rabbit Alexa fluor-594 (Invitrogen). Images were acquired by the Axio Observer  
428 system combined with the LSM 780 confocal device microscope at 63x  
429 magnification (Carl Zeiss).

430

#### 431 ***Histological Evaluation***

432 Paraffin-embedded lung tissues sections (3  $\mu$ m) were stained by standard  
433 hematoxylin and eosin (H&E). Morphological lung injury patterns were  
434 evaluated by specialized pulmonary pathologists (ATF) blinded to clinical  
435 history. They were classified as absent or present with its extent of lung injury  
436 area by 5% cut-offs in Fibrosis, Organizing Pneumonia (OP), Acute Fibrinous

437 and Organizing Pneumonia (AFOP), Diffuse Alveolar Damage (DAD), Cellular  
438 Pneumonitis, Thrombus Formation.

439

440 ***RNA extraction and Real-Time Polymerase Chain Reaction for***  
441 ***inflammatory genes***

442 Total RNA from fresh lung tissue of SARS-CoV-2 patients and controls was  
443 obtained using Trizol reagent, and purification was performed according to the  
444 manufacturer's instructions. The RNA was quantified by spectrophotometry in a  
445 NanoDrop 2000c spectrophotometer. The concentration was adjusted to 1  
446  $\mu\text{g}/\mu\text{L}$ , and the RNA was stored at  $-70\text{ }^\circ\text{C}$  until reverse transcription. For  
447 inflammatory genes qPCR the total RNA was transcribed into complementary  
448 DNA (cDNA) using a High-Capacity cDNA Reverse Transcription kit (without an  
449 inhibitor) according to the protocol provided by the manufacturer (Thermo  
450 Fisher, Carlsbad, CA, USA). The reaction was prepared in a final volume of  
451  $20.0\text{ }\mu\text{L}$  containing  $4.2\text{ }\mu\text{L}$  of  $\text{H}_2\text{O}$ ,  $2.0\text{ }\mu\text{L}$  of buffer,  $2.0\text{ }\mu\text{L}$  of random primers,  
452  $0.8\text{ }\mu\text{L}$  of dNTP Mix (100 mM),  $1.0\text{ }\mu\text{L}$  of reverse transcriptase (RT) enzyme and  
453  $1\text{ }\mu\text{L}$  of RNA ( $1\text{ }\mu\text{g}/\mu\text{L}$ ). The solution was then placed into a thermocycler with  
454 the following program:  $25\text{ }^\circ\text{C}$  for 10 min,  $37\text{ }^\circ\text{C}$  for 120 min and  $85\text{ }^\circ\text{C}$  for 5 min.  
455 The real-time PCR was performed in 96-well plates using Sybr Green reagents  
456 (Applied Biosystems, Waltham, MA, USA) and a Quant studio real-time PCR  
457 system (Applied Biosystems, Foster City, CA, USA). The real time-RT-PCR was  
458 carried out in a total volume of  $20\text{ }\mu\text{l}$  on a 96-well MicroAmp Fast Optical plate  
459 (Applied Biosystems). Each well contained  $10\text{ }\mu\text{l}$  SYBR Green qPCR Master  
460 Mix (ThermoFisher),  $1\text{ }\mu\text{l}$  of each primer (**Supplementary Table 1**),  $2\text{ }\mu\text{l}$  cDNA  
461 ( $20\text{ ng}$ ) and  $7\text{ }\mu\text{l}$  RNase free water using the following protocol: initial  
462 denaturation at  $95\text{ }^\circ\text{C}$  for 10 min, 40 cycles of denaturation at  $95\text{ }^\circ\text{C}$  for 15 s  
463 followed by annealing/extension at  $60\text{ }^\circ\text{C}$  for 60 s. Each PCR was followed by a  
464 dissociation curve analysis between  $60\text{-}95\text{ }^\circ\text{C}$ . The Ct values were analyzed by  
465 the comparative Ct ( $\Delta\Delta\text{Ct}$ ) method and normalized to the endogenous control  
466 GAPDH. Fold difference was calculated as  $2^{-\Delta\Delta\text{Ct}}$

467

## 468 ***Real-Time Polymerase Chain Reaction for Viral RNA***

469 Detection and quantification of SARS-CoV-2 genes was performed with primer-  
470 probe sets for 2019-nCoV\_N2 and gene E, according to US Centers for  
471 Disease Control and Prevention (Lu et al., 2020) and Charité group protocols  
472 (Corman et al., 2020). The genes evaluated (N2, E, and RNase-P  
473 housekeeping gene) were tested by one-step real-time RT-PCR using total  
474 nucleic acids extracted with TRIzol (Invitrogen). All real-time PCR assays were  
475 done on a Quant studio real-time PCR system (Applied Biosystems, Foster City,  
476 CA, USA). A total of 70 ng of RNA was used for genome amplification, adding  
477 specific primers (20 µM), and probe (5 µM), and with TaqPath 1-Step  
478 quantitative RT-PCR Master Mix (Applied Biosystems), with the following  
479 parameters: 25°C for 2 min, 50°C for 15 min, and 95°C for 2 min, followed by 45  
480 cycles of 94°C for 5 s and 60°C for 30 s. Primers used were the following: N2  
481 forward: 5'-TTACAAACATTGGCCGCAAA-3', N2 reverse: 5'-  
482 GCGCGACATTCCGAAGAA-3'; N2 probe: 5'-FAM-  
483 ACAATTTGCCCCCAGCGCTTCAG-BHQ1-3' (Lu et al., 2020); E forward: 5'-  
484 ACAGGTACGTTAATAGTTAATAGCGT-3', E reverse: 5'-  
485 ATATTGCAGCAGTACGCACACA-3'; E probe: 5'-AM-  
486 AACTAGCCATCCTTACTGCGCTTCG-BHQ-1-3' (Corman et al., 2020);  
487 RNase-P forward: 5'-AGATTTGGACCTGCGAGCG-3', RNase-P reverse: 5'-  
488 GAGCGGCTGTCTCCACAAGT-3'; and RNase-P probe: 5'-FAM-  
489 TTCTGACCTGAAGGCTCTGCGCG-BHQ-1-3' (Lu et al., 2020). A plasmid of  
490 N2 protein and E protein was used for a standard curve construction for viral  
491 load quantification.

## 492 ***Chest computed tomography images acquisition and evaluation***

493 Chest x-radiography (CXR) and computed tomography (CT) exams were  
494 performed as part of the routine clinical evaluation. Chest radiographies were  
495 performed in conventional equipment, mainly in the anteroposterior incidence.  
496 CT images were performed in multidetector scanners (Brilliance CT Big Bore 16  
497 - Philips, Holland, or Aquilion Prime 160 - Toshiba, Japan), using similar  
498 protocols for the acquisition of high-resolution images of the lungs (Raghu et al.,  
499 2018). Patients were scanned in the supine position without the administration  
500 of intravenous contrast media. Typical acquisition parameters were: 120 kVp

501 tube voltage, 100–140 ref mAs (Koenigkam-Santos et al., 2022), 0.3–0.7 s  
502 gantry rotation time, reconstruction matrix size of 512×512, slice thickness, and  
503 increment of 1.0 mm, using standard (soft) and hard kernel filters. Imaging  
504 exams were independently evaluated by two thoracic radiologists (MKS and  
505 DTW), blinded to clinical data, laboratory, and pathology results as described  
506 (Koenigkam-Santos et al., 2022). Divergences were solved by consensus. All  
507 CXRs available were classified for the presence and grade of viral pneumonia  
508 (Revel et al., 2020). Pulmonary disease evolution on imaging was evaluated  
509 considering all exams from the initial to the last image before death.  
510 Tomographic images were evaluated similarly to CXR images.

511

### 512 **Statistical Analysis**

513 For puncta quantification, all histological sections were viewed on a 63x  
514 objective for digitalizing random images using the LSM 780 system in the Axio  
515 Observer microscope, covering an area of about ~1.7 mm<sup>2</sup> of lung parenchyma  
516 analyzed per case. Manual counting of puncta and cells was blinded and  
517 performed using the acquired images. Morphometric analyzes were performed  
518 as described (Weibel, 1963). The quantification of expression by  
519 immunohistochemistry was performed by calculating the percentage of marked  
520 area, the scanned images were opened in the ImageJ software, using the IHQ  
521 Toolbox plugin, which consists of a semi-automatic color selection tool that  
522 selects the pixels positive for immunohistochemical marking, differentiating  
523 them from background and H&E marking, after selecting the positive pixels, the  
524 images were transformed into 8-bits and the area occupied by these tones was  
525 calculated. The distribution of the gene expression and biochemical marker and  
526 puncta count data was evaluated using the Shapiro–Wilk test; the data were  
527 analyzed using non-parametric Kruskal-Wallis, Mann-Whitney test and  
528 Spearman correlation. The data as violin plot graphs show median and  
529 quartiles. Statistical analyzes were performed using the GraphPad PRISM 5.0  
530 program, with p<0.05 being considered statistically significant. Heatmaps were  
531 constructed using the heatmap.2 function in the R program (Project for  
532 Statistical Computing, version 3.4.1), the hierarchical clustering method used a  
533 correlation distance measure with ward.D2 and Canberra analysis.

534

535 **Acknowledgments:** We would like to thank Maira Nakamura, Amanda Zuin  
536 and Dr. Roberta Sales for technical support.

537

538 **Funding:** Fundação de Amparo à Pesquisa do Estado de Sao Paulo, FAPESP  
539 grants 2013/08216-2, 2019/11342-6 and 2020/04964-8. Conselho Nacional de  
540 Desenvolvimento Científico e Tecnológico, CNPq grant 303021/2020-9.  
541 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES grant  
542 88887.507253/2020-00.

543

544 **Competing interests:** Authors declare that they have no competing interests.

545



## 546 References

547

- 548 Batah, S.S., and A.T. Fabro. 2021. Pulmonary pathology of ARDS in COVID-19:  
549 A pathological review for clinicians. *Respir Med* 176:106239.
- 550 Bösmüller, H., M. Matter, F. Fend, and A. Tzankov. 2021. The pulmonary  
551 pathology of COVID-19. *Virchows Arch* 478:137–150.
- 552 Broz, P., and V.M. Dixit. 2016. Inflammasomes: mechanism of assembly,  
553 regulation and signalling. *Nat Rev Immunol* 16:407-420.
- 554 Cama, V.F., J. Marín-Prida, N. Acosta-Rivero, E.F. Acosta, L.O. Díaz, A.V.  
555 Casadesús, B. Fernández-Marrero, N. Gilva-Rodríguez, D. Cremata-  
556 García, M. Cervantes-Llanos, B. Piniella-Matamoros, D. Sánchez, L. Del  
557 Rosario-Cruz, I. Borrajero, A. Díaz, Y. González, E. Pentón-Arias, T.  
558 Montero-González, G. Guillen-Nieto, and G. Pentón-Rol. 2021. The  
559 microglial NLRP3 inflammasome is involved in human SARS-CoV-2  
560 cerebral pathogenicity: A report of three post-mortem cases. *J*  
561 *Neuroimmunol* 361:577728.
- 562 Campos, J., T. Ponomaryov, A. De Prendergast, K. Whitworth, C.W. Smith,  
563 A.O. Khan, D. Kavanagh, and A. Brill. 2021. Neutrophil extracellular traps  
564 and inflammasomes cooperatively promote venous thrombosis in mice.  
565 *Blood Adv* 5:2319-2324.
- 566 Chen, H., W. Liu, Y. Wang, D. Liu, L. Zhao, and J. Yu. 2021. SARS-CoV-2  
567 activates lung epithelial cell proinflammatory signaling and leads to immune  
568 dysregulation in COVID-19 patients. *EBioMedicine* 70:103500.
- 569 Cho, S.J., J.S. Moon, K. Nikahira, H.S. Yun, R. Harris, K.S. Hong, H. Huang,  
570 A.M.K. Choi, and H. Stout-Delgado. 2020. GLUT1-dependent glycolysis  
571 regulates exacerbation of fibrosis via AIM2 inflammasome activation.  
572 *Thorax* 75:227-236.
- 573 Corman, V.M., O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T.  
574 Bleicker, S. Brünink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L.  
575 Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski,  
576 J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken,  
577 M.P. Koopmans, and C. Drosten. 2020. Detection of 2019 novel  
578 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin*  
579 *Europeen sur les maladies transmissibles = European communicable*  
580 *disease bulletin* 25:
- 581 Cui, H., and L. Zhang. 2020. Key Components of Inflammasome and Pyroptosis  
582 Pathways Are Deficient in Canines and Felines, Possibly Affecting Their  
583 Response to SARS-CoV-2 Infection. *Front Immunol* 11:592622.
- 584 Delorey, T.M., C.G.K. Ziegler, G. Heimberg, R. Normand, Y. Yang, Å.  
585 Segerstolpe, D. Abbondanza, S.J. Fleming, A. Subramanian, D.T. Montoro,  
586 K.A. Jagadeesh, K.K. Dey, P. Sen, M. Slyper, Y.H. Pita-Juárez, D. Phillips,  
587 J. Biermann, Z. Bloom-Ackermann, N. Barkas, A. Ganna, J. Gomez, J.C.  
588 Melms, I. Katsyv, E. Normandin, P. Naderi, Y.V. Popov, S.S. Raju, S.  
589 Niezen, L.T. Tsai, K.J. Siddle, M. Sud, V.M. Tran, S.K. Vellarikkal, Y. Wang,  
590 L. Amir-Zilberstein, D.S. Atri, J. Beechem, O.R. Brook, J. Chen, P. Divakar,  
591 P. Dorceus, J.M. Engreitz, A. Essene, D.M. Fitzgerald, R. Fropf, S. Gazal,  
592 J. Gould, J. Grzyb, T. Harvey, J. Hecht, T. Hether, J. Jané-Valbuena, M.  
593 Leney-Greene, H. Ma, C. McCabe, D.E. McLoughlin, E.M. Miller, C. Muus,

- 594 M. Niemi, R. Padera, L. Pan, D. Pant, C. Pe'er, J. Pfiffner-Borges, C.J.  
595 Pinto, J. Plaisted, J. Reeves, M. Ross, M. Rudy, E.H. Rueckert, M.  
596 Siciliano, A. Sturm, E. Todres, A. Waghray, S. Warren, S. Zhang, D.R.  
597 Zollinger, L. Cosimi, R.M. Gupta, N. Hacohen, H. Hibshoosh, W. Hide, A.L.  
598 Price, J. Rajagopal, P.R. Tata, S. Riedel, G. Szabo, T.L. Tickle, P.T. Ellinor,  
599 D. Hung, P.C. Sabeti, R. Novak, R. Rogers, D.E. Ingber, Z.G. Jiang, D.  
600 Juric, M. Babadi, S.L. Farhi, B. Izar, J.R. Stone, I.S. Vlachos, I.H. Solomon,  
601 O. Ashenberg, C.B.M. Porter, B. Li, A.K. Shalek, A.C. Villani, O. Rozenblatt-  
602 Rosen, and A. Regev. 2021. COVID-19 tissue atlases reveal SARS-CoV-2  
603 pathology and cellular targets. *Nature* 595:107-113.
- 604 Dolinay, T., Y.S. Kim, J. Howrylak, G.M. Hunninghake, C.H. An, L.  
605 Fredenburgh, A.F. Massaro, A. Rogers, L. Gazourian, K. Nakahira, J.A.  
606 Haspel, R. Landazury, S. Eppanapally, J.D. Christie, N.J. Meyer, L.B. Ware,  
607 D.C. Christiani, S.W. Ryter, R.M. Baron, and A.M. Choi. 2012.  
608 Inflammasome-regulated cytokines are critical mediators of acute lung  
609 injury. *American journal of respiratory and critical care medicine* 185:1225-  
610 1234.
- 611 Eisfeld, H.S., A. Simonis, S. Winter, J. Chhen, L.J. Ströh, T. Krey, M. Koch, S.J.  
612 Theobald, and J. Rybniker. 2021. Viral Glycoproteins Induce NLRP3  
613 Inflammasome Activation and Pyroptosis in Macrophages. *Viruses* 13:  
614 Glass, G., J.A. Papin, and J.W. Mandell. 2009. SIMPLE: a sequential  
615 immunoperoxidase labeling and erasing method. *J Histochem Cytochem*  
616 57:899-905.
- 617 Hariri, L.P., C.M. North, A.R. Shih, R.A. Israel, J.H. Maley, J.A. Villalba, V.  
618 Vinarsky, J. Rubin, D.A. Okin, A. Sclafani, J.W. Alladina, J.W. Griffith, M.A.  
619 Gillette, Y. Raz, C.J. Richards, A.K. Wong, A. Ly, Y.P. Hung, R.R.  
620 Chivukula, C.R. Petri, T.F. Calhoun, L.N. Brenner, K.A. Hibbert, B.D.  
621 Medoff, C.C. Hardin, J.R. Stone, and M. Mino-Kenudson. 2021. Lung  
622 Histopathology in Coronavirus Disease 2019 as Compared With Severe  
623 Acute Respiratory Syndrome and H1N1 Influenza: A Systematic Review.  
624 *Chest* 159:73-84.
- 625 Hauenstein, A.V., L. Zhang, and H. Wu. 2015. The hierarchical structural  
626 architecture of inflammasomes, supramolecular inflammatory machines.  
627 *Current opinion in structural biology* 31:75-83.
- 628 Hottz, E.D., I.G. Azevedo-Quintanilha, L. Palhinha, L. Teixeira, E.A. Barreto,  
629 C.R.R. Pao, C. Righy, S. Franco, T.M.L. Souza, P. Kurtz, F.A. Bozza, and  
630 P.T. Bozza. 2020. Platelet activation and platelet-monocyte aggregate  
631 formation trigger tissue factor expression in patients with severe COVID-19.  
632 *Blood* 136:1330-1341.
- 633 Huang, K.J., I.J. Su, M. Theron, Y.C. Wu, S.K. Lai, C.C. Liu, and H.Y. Lei. 2005.  
634 An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol*  
635 75:185-194.
- 636 Hussain, S., S. Sangtian, S.M. Anderson, R.J. Snyder, J.D. Marshburn, A.B.  
637 Rice, J.C. Bonner, and S. Garantziotis. 2014. Inflammasome activation in  
638 airway epithelial cells after multi-walled carbon nanotube exposure  
639 mediates a profibrotic response in lung fibroblasts. *Part Fibre Toxicol* 11:28.
- 640 Jones, H.D., T.R. Crother, R.A. Gonzalez-Villalobos, M. Jupelli, S. Chen, J.  
641 Dagvadorj, M. Arditi, and K. Shimada. 2014. The NLRP3 inflammasome is  
642 required for the development of hypoxemia in LPS/mechanical ventilation  
643 acute lung injury. *Am J Respir Cell Mol Biol* 50:270-280.



- 644 Junqueira, C., Â. Crespo, S. Ranjbar, L.B. de Lacerda, M. Lewandrowski, J.  
645 Ingber, B. Parry, S. Ravid, S. Clark, M.R. Schrimpf, F. Ho, C. Beakes, J.  
646 Margolin, N. Russell, K. Kays, J. Boucau, U. Das Adhikari, S.M. Vora, V.  
647 Leger, L. Gehrke, L. Henderson, E. Janssen, D. Kwon, C. Sander, J.  
648 Abraham, M.B. Goldberg, H. Wu, G. Mehta, S. Bell, A.E. Goldfeld, M.R.  
649 Filbin, and J. Lieberman. 2022. FcyR-mediated SARS-CoV-2 infection of  
650 monocytes activates inflammation. *Nature*
- 651 Koenigkam-Santos, M., D.T. Wada, M.N. Benatti, L. Siyuan, S.S. Batah, A.A.  
652 Cetlin, M.B. de Menezes, and A.T. Fabro. 2022. SARS-Cov-2 pneumonia  
653 phenotyping on imaging exams of patients submitted to minimally invasive  
654 autopsy. *Ann Transl Med* 10:140.
- 655 Kolliputi, N., R.S. Shaik, and A.B. Waxman. 2010. The inflammasome mediates  
656 hyperoxia-induced alveolar cell permeability. *J Immunol* 184:5819-5826.
- 657 Kommos, F.K.F., C. Schwab, L. Tavernar, J. Schreck, W.L. Wagner, U. Merle,  
658 D. Jonigk, P. Schirmacher, and T. Longerich. 2020. The Pathology of  
659 Severe COVID-19-Related Lung Damage. *Dtsch Arztebl Int* 117:500-506.
- 660 Kucia, M., J. Ratajczak, K. Bujko, M. Adamiak, A. Ciechanowicz, V. Chumak, K.  
661 Brzezniakiewicz-Janus, and M.Z. Ratajczak. 2021. An evidence that SARS-  
662 Cov-2/COVID-19 spike protein (SP) damages hematopoietic  
663 stem/progenitor cells in the mechanism of pyroptosis in Nlrp3  
664 inflammasome-dependent manner. *Leukemia* 1-4.
- 665 Kuipers, M.T., H. Aslami, J.R. Janczy, K.F. van der Sluijs, A.P. Vlaar, E.K.  
666 Wolthuis, G. Choi, J.J. Roelofs, R.A. Flavell, F.S. Sutterwala, P. Bresser,  
667 J.C. Leemans, T. van der Poll, M.J. Schultz, and C.W. Wieland. 2012.  
668 Ventilator-induced lung injury is mediated by the NLRP3 inflammasome.  
669 *Anesthesiology* 116:1104-1115.
- 670 Libby, P., and T. Lüscher. 2020. COVID-19 is, in the end, an endothelial  
671 disease. *Eur Heart J* 41:3038-3044.
- 672 Liu, J., Y. Li, Q. Liu, Q. Yao, X. Wang, H. Zhang, R. Chen, L. Ren, J. Min, F.  
673 Deng, B. Yan, L. Liu, Z. Hu, M. Wang, and Y. Zhou. 2021. SARS-CoV-2 cell  
674 tropism and multiorgan infection. In *Cell Discov.* 17.
- 675 Lu, X., L. Wang, S.K. Sakthivel, B. Whitaker, J. Murray, S. Kamili, B. Lynch, L.  
676 Malapati, S.A. Burke, J. Harcourt, A. Tamin, N.J. Thornburg, J.M.  
677 Villanueva, and S. Lindstrom. 2020. US CDC Real-Time Reverse  
678 Transcription PCR Panel for Detection of Severe Acute Respiratory  
679 Syndrome Coronavirus 2. *Emerg Infect Dis* 26:1654-1665.
- 680 Lucas, C.W., P. LKlein, J. et al. 2020. Longitudinal analyses reveal  
681 immunological misfiring in severe COVID-19. *Nature*
- 682 Lv, Z., Y. Wang, Y.J. Liu, Y.F. Mao, W.W. Dong, Z.N. Ding, G.X. Meng, L.  
683 Jiang, and X.Y. Zhu. 2018. NLRP3 Inflammasome Activation Contributes to  
684 Mechanical Stretch-Induced Endothelial-Mesenchymal Transition and  
685 Pulmonary Fibrosis. *Crit Care Med* 46:e49-e58.
- 686 Meng, Y., T. Li, G.S. Zhou, Y. Chen, C.H. Yu, M.X. Pang, W. Li, Y. Li, W.Y.  
687 Zhang, and X. Li. 2015. The angiotensin-converting enzyme 2/angiotensin  
688 (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by  
689 inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway.  
690 *Antioxid Redox Signal* 22:241-258.
- 691 Meng, Y., M. Pan, B. Zheng, Y. Chen, W. Li, Q. Yang, Z. Zheng, N. Sun, Y.  
692 Zhang, and X. Li. 2019. Autophagy Attenuates Angiotensin II-Induced  
693 Pulmonary Fibrosis by Inhibiting Redox Imbalance-Mediated NOD-Like

- 694 Receptor Family Pyrin Domain Containing 3 Inflammasome Activation.  
695 *Antioxid Redox Signal* 30:520-541.
- 696 Nuovo, G.J., C. Magro, T. Shaffer, H. Awad, D. Suster, S. Mikhail, B. He, J.J.  
697 Michaille, B. Liechty, and E. Tili. 2021. Endothelial cell damage is the  
698 central part of COVID-19 and a mouse model induced by injection of the S1  
699 subunit of the spike protein. *Annals of diagnostic pathology* 51:151682.
- 700 Olajide, O.A., V.U. Iwuanyanwu, I. Lepiarz-Raba, and A.A. Al-Hindawi. 2021.  
701 Induction of Exaggerated Cytokine Production in Human Peripheral Blood  
702 Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1  
703 and Its Inhibition by Dexamethasone. *Inflammation* 44:1865-1877.
- 704 Paul, O., J.Q. Tao, L. Litzky, M. Feldman, K. Montone, C. Rajapakse, C.  
705 Bermudez, and S. Chatterjee. 2021. Vascular Inflammation in Lungs of  
706 Patients with Fatal Coronavirus Disease 2019 (COVID-19) Infection:  
707 Possible role for the NLRP3 inflammasome. *medRxiv*
- 708 Polak, S.B., I.C. Van Gool, D. Cohen, J.H. von der Thüsen, and J. van Paassen.  
709 2020. A systematic review of pathological findings in COVID-19: a  
710 pathophysiological timeline and possible mechanisms of disease  
711 progression. *Mod Pathol* 33:2128-2138.
- 712 Pontelli, M.C., I.A. Castro, R.B. Martins, L. La Serra, F.P. Veras, D.C.  
713 Nascimento, C.M. Silva, R.S. Cardoso, R. Rosales, R. Gomes, T.M. Lima,  
714 J.P. Souza, B.C. Vitti, D.B. Caetite, M.H.F. de Lima, S.D. Stumpf, C.E.  
715 Thompson, L.M. Bloyet, J.T.E. Kawahisa, M.C. Giannini, L.P. Bonjorno,  
716 M.I.F. Lopes, S.S. Batah, S. Li, R.L. Assad, S.C.L. Almeida, F.R. Oliveira,  
717 M.N. Benatti, L.L.F. Pontes, R.C. Santana, F.C. Vilar, M.A. Martins, P.Y.  
718 Shi, T.M. Cunha, R.T. Calado, J.C. Alves-Filho, D.S. Zamboni, A. Fabro, P.  
719 Louzada-Junior, R.D.R. Oliveira, S.P.J. Whelan, F.Q. Cunha, and E.  
720 Arruda. 2022. SARS-CoV-2 productively infects primary human immune  
721 system cells in vitro and in COVID-19 patients. *J Mol Cell Biol*
- 722 Postlethwaite, A.E., R. Raghov, G.P. Stricklin, H. Poppleton, J.M. Seyer, and  
723 A.H. Kang. 1988. Modulation of fibroblast functions by interleukin 1:  
724 increased steady-state accumulation of type I procollagen messenger RNAs  
725 and stimulation of other functions but not chemotaxis by human  
726 recombinant interleukin 1 alpha and beta. *J Cell Biol* 106:311-318.
- 727 Qin, C., L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, C. Xie, K. Ma, K. Shang, W.  
728 Wang, and D.S. Tian. 2020. Dysregulation of Immune Response in Patients  
729 With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*  
730 71:762-768.
- 731 Raghu, G., M. Remy-Jardin, J.L. Myers, L. Richeldi, C.J. Ryerson, D.J. Lederer,  
732 J. Behr, V. Cottin, S.K. Danoff, F. Morell, K.R. Flaherty, A. Wells, F.J.  
733 Martinez, A. Azuma, T.J. Bice, D. Bouros, K.K. Brown, H.R. Collard, A.  
734 Duggal, L. Galvin, Y. Inoue, R.G. Jenkins, T. Johkoh, E.A. Kazerooni, M.  
735 Kitaichi, S.L. Knight, G. Mansour, A.G. Nicholson, S.N.J. Pipavath, I.  
736 Buendia-Roldan, M. Selman, W.D. Travis, S. Walsh, K.C. Wilson,  
737 E.R.S.J.R.S. American Thoracic Society, and S. Latin American Thoracic.  
738 2018. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official  
739 ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American journal of*  
740 *respiratory and critical care medicine* 198:e44-e68.
- 741 Ratajczak, M.Z., K. Bujko, A. Ciechanowicz, K. Sielatycka, M. Cymer, W.  
742 Marlicz, and M. Kucia. 2021. SARS-CoV-2 Entry Receptor ACE2 Is  
743 Expressed on Very Small CD45(-) Precursors of Hematopoietic and

- 744 Endothelial Cells and in Response to Virus Spike Protein Activates the  
745 Nlrp3 Inflammasome. *Stem Cell Rev Rep* 17:266-277.
- 746 Revel, M.P., A.P. Parkar, H. Prosch, M. Silva, N. Sverzellati, F. Gleeson, A.  
747 Brady, R. European Society of, and I. the European Society of Thoracic.  
748 2020. COVID-19 patients and the radiology department - advice from the  
749 European Society of Radiology (ESR) and the European Society of  
750 Thoracic Imaging (ESTI). *Eur Radiol* 30:4903-4909.
- 751 Rodrigues, T.S., K.S.G. de Sá, A.Y. Ishimoto, A. Becerra, S. Oliveira, L.  
752 Almeida, A.V. Gonçalves, D.B. Perucello, W.A. Andrade, R. Castro, F.P.  
753 Veras, J.E. Toller-Kawahisa, D.C. Nascimento, M.H.F. de Lima, C.M.S.  
754 Silva, D.B. Caetite, R.B. Martins, I.A. Castro, M.C. Pontelli, F.C. de Barros,  
755 N.B. do Amaral, M.C. Giannini, L.P. Bonjorno, M.I.F. Lopes, R.C. Santana,  
756 F.C. Vilar, M. Auxiliadora-Martins, R. Luppino-Assad, S.C.L. de Almeida,  
757 F.R. de Oliveira, S.S. Batah, L. Siyuan, M.N. Benatti, T.M. Cunha, J.C.  
758 Alves-Filho, F.Q. Cunha, L.D. Cunha, F.G. Frantz, T. Kohlsdorf, A.T. Fabro,  
759 E. Arruda, R.D.R. de Oliveira, P. Louzada-Junior, and D.S. Zamboni. 2021.  
760 Inflammasomes are activated in response to SARS-CoV-2 infection and are  
761 associated with COVID-19 severity in patients. *J Exp Med* 218:
- 762 Sauter, J.L., M.K. Baine, K.J. Butnor, D.J. Buonocore, J.C. Chang, A.A.  
763 Jungbluth, M.J. Szabolcs, S. Morjaria, S.L. Mount, N. Rekhman, E. Selbs,  
764 Z.M. Sheng, Y. Xiao, D.E. Kleiner, S. Pittaluga, J.K. Taubenberger, A.V.  
765 Rapkiewicz, and W.D. Travis. 2020. Insights into pathogenesis of fatal  
766 COVID-19 pneumonia from histopathology with immunohistochemical and  
767 viral RNA studies. *Histopathology* 77:915-925.
- 768 Schimmel, L., K.Y. Chew, C.J. Stocks, T.E. Yordanov, P. Essebier, A.  
769 Kulasinghe, J. Monkman, A.F.R. Dos Santos Miggiolaro, C. Cooper, L. de  
770 Noronha, K. Schroder, A.K. Lagendijk, L.I. Labzin, K.R. Short, and E.J.  
771 Gordon. 2021. Endothelial cells are not productively infected by SARS-CoV-  
772 2. *Clin Transl Immunology* 10:e1350.
- 773 Sefik, E., R. Qu, C. Junqueira, E. Kaffe, H. Mirza, J. Zhao, J.R. Brewer, A. Han,  
774 H.R. Steach, B. Israelow, H.N. Blackburn, S. Velazquez, Y.G. Chen, S.  
775 Halene, A. Iwasaki, E. Meffre, M. Nussenzweig, J. Lieberman, C.B. Wilen,  
776 Y. Kluger, and R.A. Flavell. 2022. Inflammasome activation in infected  
777 macrophages drives COVID-19 pathology. *Nature*
- 778 Sinha, P., M.A. Matthay, and C.S. Calfee. 2020. Is a "Cytokine Storm" Relevant  
779 to COVID-19? In *JAMA Intern Med*. United States. 1152-1154.
- 780 Sun, B., X. Wang, Y.P. Liao, Z. Ji, C.H. Chang, S. Pokhrel, J. Ku, X. Liu, M.  
781 Wang, D.R. Dunphy, R. Li, H. Meng, L. Mädler, C.J. Brinker, A.E. Nel, and  
782 T. Xia. 2016. Repetitive Dosing of Fumed Silica Leads to Profibrogenic  
783 Effects through Unique Structure-Activity Relationships and Biopersistence  
784 in the Lung. *ACS Nano* 10:8054-8066.
- 785 Sur, S., R. Steele, T.S. Isbell, R. Ray, and R.B. Ray. 2022. Circulatory  
786 Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in  
787 Endothelial Cells. *mBio* 13:e0095122.
- 788 Taylor, F.B., Jr., C.H. Toh, W.K. Hoots, H. Wada, M. Levi, T. Scientific  
789 Subcommittee on Disseminated Intravascular Coagulation of the  
790 International Society on, and Haemostasis. 2001. Towards definition,  
791 clinical and laboratory criteria, and a scoring system for disseminated  
792 intravascular coagulation. *Thromb Haemost* 86:1327-1330.

- 793 Toldo, S., R. Bussani, V. Nuzzi, A. Bonaventura, A.G. Mauro, A. Cannatà, R.  
794 Pillappa, G. Sinagra, P. Nana-Sinkam, P. Sime, and A. Abbate. 2021.  
795 Inflammasome formation in the lungs of patients with fatal COVID-19.  
796 *Inflamm Res* 70:7-10.
- 797 Varga, Z., A.J. Flammer, P. Steiger, M. Haberecker, R. Andermatt, A.S.  
798 Zinkernagel, M.R. Mehra, R.A. Schuepbach, F. Ruschitzka, and H. Moch.  
799 2020. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*  
800 395:1417-1418.
- 801 Ward, S.E., G.F. Curley, M. Lavin, H. Fogarty, E. Karampini, N.L. McEvoy, J.  
802 Clarke, M. Boylan, R. Alalqam, A.P. Worrall, C. Kelly, E. de Barra, S.  
803 Glavey, C. Ni Cheallaigh, C. Bergin, I. Martin-Loeches, L. Townsend, P.W.  
804 Mallon, J.M. O'Sullivan, and J.S. O'Donnell. 2021. Von Willebrand factor  
805 propeptide in severe coronavirus disease 2019 (COVID-19): evidence of  
806 acute and sustained endothelial cell activation. *Br J Haematol* 192:714-719.
- 807 Weibel, E.R. 1963. Principles and methods for the morphometric study of the  
808 lung and other organs. *Lab Invest* 12:131-155.
- 809 WHO. 2020. World Health Organization, <https://covid19.who.int/>.
- 810 Wu, C., W. Lu, Y. Zhang, G. Zhang, X. Shi, Y. Hisada, S.P. Grover, X. Zhang, L.  
811 Li, B. Xiang, J. Shi, X.A. Li, A. Daugherty, S.S. Smyth, D. Kirchhofer, T.  
812 Shiroishi, F. Shao, N. Mackman, Y. Wei, and Z. Li. 2019. Inflammasome  
813 Activation Triggers Blood Clotting and Host Death through Pyroptosis.  
814 *Immunity* 50:1401-1411.e1404.
- 815 Wu, J., Z. Yan, D.E. Schwartz, J. Yu, A.B. Malik, and G. Hu. 2013. Activation of  
816 NLRP3 inflammasome in alveolar macrophages contributes to mechanical  
817 stretch-induced lung inflammation and injury. *J Immunol* 190:3590-3599.
- 818 Xiang, M., X. Shi, Y. Li, J. Xu, L. Yin, G. Xiao, M.J. Scott, T.R. Billiar, M.A.  
819 Wilson, and J. Fan. 2011. Hemorrhagic shock activation of NLRP3  
820 inflammasome in lung endothelial cells. *J Immunol* 187:4809-4817.
- 821 Xu, P., Z. Wen, X. Shi, Y. Li, L. Fan, M. Xiang, A. Li, M.J. Scott, G. Xiao, S. Li,  
822 T.R. Billiar, M.A. Wilson, and J. Fan. 2013. Hemorrhagic shock augments  
823 Nlrp3 inflammasome activation in the lung through impaired pyrin induction.  
824 *J Immunol* 190:5247-5255.
- 825 Xu, Z., L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu,  
826 L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, and F.S.  
827 Wang. 2020. Pathological findings of COVID-19 associated with acute  
828 respiratory distress syndrome. *Lancet Respir Med* 8:420-422.
- 829 Yang, J., Y. Zhao, P. Zhang, Y. Li, Y. Yang, J. Zhu, X. Song, G. Jiang, and J.  
830 Fan. 2016. Hemorrhagic shock primes for lung vascular endothelial cell  
831 pyroptosis: role in pulmonary inflammation following LPS. *Cell Death Dis*  
832 7:e2363.
- 833 Zhang, Y., J. Cui, G. Zhang, C. Wu, A. Abdel-Latif, S.S. Smyth, T. Shiroishi, N.  
834 Mackman, Y. Wei, M. Tao, and Z. Li. 2021. Inflammasome activation  
835 promotes venous thrombosis through pyroptosis. *Blood Adv* 5:2619-2623.
- 836 Zhang, Y., G. Liu, R.O. Dull, D.E. Schwartz, and G. Hu. 2014. Autophagy in  
837 pulmonary macrophages mediates lung inflammatory injury via NLRP3  
838 inflammasome activation during mechanical ventilation. *Am J Physiol Lung*  
839 *Cell Mol Physiol* 307:L173-185.

840



**Table 1.** COVID-19 patient characteristics

<b>Demographic Characteristics</b>	Mean ( $\pm$ SD) or N (%)
N	47
Sex	
Female	23 (48.93%)
Age (years)	67.97 (15.05 $\pm$ )
Illness Time (days)	18.08 (11.04 $\pm$ )
ICU	37 (78.72%)
<b>Comorbidities</b>	
Hypertension	26 (55.32%)
BMI	31.10 ( $\pm$ 8.82)
Diabetes	18 (38.29%)
History of smoking	12 (25.53%)
Heart disease	12 (25.53%)
Lung disease	12 (25.53%)
Kidney disease	7 (14.89%)
History of stroke	7 (14.89%)
Autoimmune diseases	2 (4.25%)
<b>Laboratorial findings</b>	
CRP (mg/dL)	11.40 ( $\pm$ 8.49)
D-Dimers ( $\mu$ g/mL)	4.91 ( $\pm$ 4.46)
LDH (mmol/L)	5.01 ( $\pm$ 5.24)
Creatinine (mg/dL)	2.22 ( $\pm$ 1.4)
Urea (mg/dL)	119.40 ( $\pm$ 58.47)
AST (IU/L)	104.42 ( $\pm$ 90.74)
ALT (IU/L)	72.12 ( $\pm$ 55.14)
AST/ALT	1.8 ( $\pm$ 1.60)
PT (INR)	1.81 ( $\pm$ 2.13)
Albumin (g/dL)	3.09 ( $\pm$ 0.58)
Blood Glucose (mg/dL)	194.72 ( $\pm$ 94.60)
<b>Respiratory status</b>	
Temperature ( $^{\circ}$ C)	37.39 ( $\pm$ 1.73)
Mechanical ventilation	36 (76.59%)
Nasal-cannula oxygen	11 (23.40%)
Intubated time (days)	12.38 ( $\pm$ 7.14)
P <sub>a</sub> O <sub>2</sub> (mmhg)	74.01 ( $\pm$ 24.63)
Venous saturation (S <sub>v</sub> O <sub>2</sub> )	67.58 ( $\pm$ 25.34)
P <sub>a</sub> O <sub>2</sub> /FiO <sub>2</sub> <sup>#</sup>	159.69 ( $\pm$ 90.84)
A-a O <sub>2</sub> Gradient Value <sup>#</sup>	283.22 ( $\pm$ 208.31)
Respiratory Rate (mov/min)	26.55 ( $\pm$ 6.80)
<b>Histopathological findings</b>	
Fibrosis (% of area)	30.00 ( $\pm$ 12.68)
Organizing Pneumonia (% of area)	10.74 ( $\pm$ 14.89)
Acute Fibrinous and Organizing Pneumonia (% of area)	6.91 ( $\pm$ 12.49)
Diffuse Alveolar Damage (% of area)	17.87 ( $\pm$ 21.05)
Pneumonitis (% of area)	22.57 ( $\pm$ 15.34)
Pulmonary infarction (% of area)	3.404 ( $\pm$ 9.618)

\* Fisher's exact test

\*\* t-Test

# Data after 18 days of hospitalization

**Table 2.** COVID-19 patient characteristics

<b>Demographic Characteristics</b>	<b>Cluster 1</b> Mean (±SD) or N (%)	<b>Cluster 2</b> Mean (±SD) or N (%)	<b>P value</b>
N	16	31	-
Sex			
Female	6 (37.50%)	17 (54.83%)	0.358*
Male	10 (62.50%)	14 (45.16%)	
Age (years)	70.81 (±10.34)	66.5 (±17.46)	0.369**
Illness Time (days)	12.06 (±6.97)	21.19 (±9.64)	0.001**
ICU	11 (68.75%)	25 (80.64%)	0.471*
<b>Comorbidities</b>			
Hypertension	10 (62.50%)	16 (51.61%)	0.546*
BMI	28.39 (±6.92)	33.21 (±8.52)	0.057**
Diabetes	7 (43.75%)	11 (35.48%)	0.999*
History of smoking	4 (25.00%)	8 (25.80%)	0.999*
Heart disease	4 (25.00%)	8 (25.80%)	0.999*
Lung disease	3 (18.75%)	9 (29.03%)	0.505*
Kidney disease	1 (6.25%)	6 (19.35%)	0.395*
History of stroke	3 (18.75%)	4 (12.90%)	0.675*
Autoimmune diseases	1 (6.25%)	1 (3.22%)	0.999*
<b>Laboratorial findings</b>			
CRP (mg/dL)	11.54 (±1.64)	11.32 (±9.15)	0.924**
D-Dimers (µg/mL)	6.07 (±5.45)	4.38 (±3.91)	0.227**
LDH (mmol/L)	6.17 (±6.42)	4.41 (±4.52)	0.280**
Creatinine (mg/dL)	2.41 (±1.64)	2.12 (±1.21)	0.494**
Urea (mg/dL)	108.36 (±53.92)	125.09 (±60.75)	0.358**
AST (IU/L)	110.65 (±112.67)	101.08 (±78.69)	0.735**
ALT (IU/L)	72.40 (±59.92)	71.98 (±53.88)	0.980**
AST/ALT	2.1 (±2.47)	1.6 (±0.92)	0.319**
PT (INR)	1.56 (±0.98)	1.95 (±2.55)	0.560**
Albumin (g/dL)	3.24 (±0.65)	3.01 (±0.54)	0.251**
Blood Glucose (mg/dL)	191.00 (±100.25)	196.65 (±96.32)	0.851**
Platelets (10 <sup>3</sup> /µl)	173.70 (±97.83)	273.10 (±128.20)	0.010**
<b>Respiratory status</b>			
Temperature (°C)	37.74 (±1.82)	37.20 (±1.62)	0.304**
Mechanical ventilation	11 (68.75%)	25 (80.64%)	0.471*
Nasal-cannula oxygen	5 (31.25%)	6 (19.35%)	0.471*
Intubated time (days)	8 (±4.72)	14.32 (±6.94)	0.009**
P <sub>a</sub> O <sub>2</sub> (mmHg)	75.54 (±8.06)	73.27 (±1.69)	0.135**
Venous saturation (S <sub>v</sub> O <sub>2</sub> )	61.33 (±27.83)	70.59 (±19.27)	0.187**
P <sub>a</sub> O <sub>2</sub> /FiO <sub>2</sub> <sup>#</sup>	216.16 (±32.94)	164.15 (±21.09)	<0.001**
A-a O <sub>2</sub> Gradient Value <sup>#</sup>	40.20 (±101.48)	237.58 (±68.05)	0.006**
Respiratory Rate (mov/min)	26.76 (±7.86)	26.45 (±5.75)	0.878**
PEEP	9.63 (±5.08)	9.62 (±4.86)	0.9611**
<b>Histopathological findings, vascular status and Inflammasome activation</b>			
Fibrosis (% of area)	24.38 (±11.59)	32.90 (±14.05)	0.042**
Organizing Pneumonia (% of area)	23.30 (±18.16)	24.50 (±15.71)	0.815**
Acute Fibrinous and Organizing Pneumonia (% of area)	18.33 (±12.24)	23.89 (±15.76)	0.225**
Diffuse Alveolar Damage (% of area)	34.00 (±24.03)	33.33 (±20.23)	0.920**
Pneumonitis (% of area)	20.67 (±18.52)	23.86 (±15.88)	0.540**
Pulmonary infarction (% of area)	26.67 (±14.14)	20.00 (±14.14)	0.132**
Disseminated Intravascular Coagulation	8 (50.00%)	5 (16.13%)	0.0198*
NLRP3 puncta per parenchyma area (mm <sup>2</sup> )	143.67 (±89.00)	238.40 (±157.76)	0.031**
Clearance Creatinine	32.94 (±22.95)	47.50 (±43.51)	0.4380**
MDRD GFR	41.58 (±30.03)	44.15 (±36.90)	0.9381**
Anticoagulation dose (mg) used close to death	14.68 (±10.07)	9.85 (±8.97)	0.0125**
Glasgow scale	7.18 (±5.70)	6.61 (±5.23)	0.7280**
SOFA score	7.12 (±2.30)	7.25 (±2.59)	0.6828**
MELD score	49.15 (±21.88)	50.91 (±40.97)	0.8113**
MODS	10.57 (±3.45)	10.39 (±3.16)	0.9946**

\* Fisher's exact test

\*\* t-Test

# Data after 18 days of hospitalization

842

843

**Table 3.** Radiological Analyzes

	<b>Cluster 1</b>	<b>Cluster 2</b>	<b>P value</b>
<b>Initial CXR pattern</b>			
No opacities	1 (6.250%)	3 (9.67%)	0.9101
Mild viral pneumonia	2 (12.50%)	3 (9.67%)	
Moderate viral pneumonia	8 (50.00%)	12 (38.70%)	
Severe viral pneumonia	5 (31.25%)	11 (35.48%)	
Impaired analysis	0	2 (6.45%)	
<b>Last CXR pattern</b>			
No opacities	1 (6.25%)	2 (6.45%)	0.9971
Mild viral pneumonia	3 (18.75%)	5 (16.12%)	
Moderate viral pneumonia	6 (37.50%)	12 (38.70%)	
Severe viral pneumonia	4 (25.00%)	8 (25.80%)	
Impaired analysis	2 (12.50%)	4 (12.90%)	
<b>Imaging evolution until death</b>			
Improvement (fewer opacities)	5 (33.33%)	10 (32.25%)	0.0364
Stability	7 (46.66%)	4 (12.90%)	
Worsening (more opacities)	2 (13.33%)	12 (38.70%)	
Impaired analysis	1 (6.66%)	5 (16.12%)	
<b>Disease Extent (Thoracic CT)</b>			
0	0	0	0.0363
<25%	4 (66.66%)	1 (12.50%)	
25-50%	0	3 (37.50%)	
50-75%	1 (16.66%)	3 (37.50%)	
>75%	1 (16.66%)	1 (12.50%)	

844

845

**Table 4.** Characteristics of COVID-19 patients who were submitted or not to mechanical ventilation (MV).

Demographics Characteristics	MV+ Mean (±SD) or n (%)	MV- Mean (±SD) or n (%)	p value
N	36	11	
Sex			
Female	17 (47.22%)	6 (54.54%)	0.7400*
Male	19 (52.77%)	5 (45.45%)	
Age (years)	65.61 (±13.52)	75.72 (±17.61)	0.0493**
Illness Time (days)	20.94 (±10.76)	8.72 (±5.40)	0.0007**
ICU	36 (100.00%)	0 (0.00%)	>0.9999*
<b>Comorbidities</b>			
Hypertension	23 (63.88%)	3 (27.27%)	0.0433*
BMI	30.61 (±8.52)	34.56 (±14.46)	0.4324**
Diabetes	16 (44.44%)	2 (18.18%)	0.1644*
History of smoking	11 (30.55%)	3 (27.77%)	>0.9999*
Heart disease	11 (30.55%)	1 (9.09%)	0.2440*
Lung disease	9 (25.00%)	2 (18.18%)	>0.9999*
Kidney disease	6 (16.66%)	1 (9.09%)	>0.9999*
History of stroke	4 (11.11%)	3 (27.77%)	0.3296*
Autoimmune diseases	1 (2.77%)	1 (9.09%)	0.4172*
<b>Laboratorial findings</b>			
CRP (mg/dL)	9.99 (±7.83)	16.02 (±9.29)	0.0377**
D-Dimers (µg/mL)	4.99 (±4.68)	4.56 (±3.62)	0.7989**
LDH (mmol/L)	5.78 (±5.76)	2.49 (±1.13)	0.0680**
Creatinine (mg/dL)	1.58 (±1.39)	1.05 (±0.50)	0.2242**
Urea (mg/dL)	138.18 (±54.07)	64.48 (±34.12)	0.0001**
AST (IU/L)	109.61 (±98.16)	84.81 (±54.14)	0.4725**
ALT (IU/L)	79.02 (±58.67)	45.38 (±26.97)	0.1254**
AST/ALT	1.6 (±1.74)	2.2 (±0.88)	0.3542**
PT (INR)	1.53 (±0.91)	2.82 (±4.24)	0.0900**
Albumin (g/dL)	2.99 (±0.54)	3.78 (±0.41)	0.0034**
Blood Glucose (mg/dL)	198.22 (±93.77)	181.11 (±102.34)	0.6340**
<b>Respiratory status</b>			
Temperature (°C)	37.51 (±1.79)	36.99 (±1.53)	0.3890**
P <sub>a</sub> O <sub>2</sub> (mmHg)	79.57 (±20.19)	53.99 (±24.12)	0.0014**
Venous saturation (S <sub>v</sub> O <sub>2</sub> )	70.86 (±14.36)	50.71 (±31.26)	0.0092**
P <sub>a</sub> O <sub>2</sub> /FiO <sub>2</sub> <sup>#</sup>	132.63 (±67.94)	257.11 (±114.86)	<0.0001**
A-a O <sub>2</sub> Gradient Value <sup>#</sup>	351.09 (±183.40)	45.69 (±26.55)	<0.0001**
Respiratory Rate (mov/min)	27.61 (±6.17)	23.09 (±7.89)	0.0669**
<b>Histopathological findings</b>			
Fibrosis (% of area)	30.28 (±14.05)	29.09 (±12.21)	0.8015**
Organizing Pneumonia (% of area)	26.11 (±13.56)	20.00 (±11.54)	0.4520**
Acute Fibrinous and Organizing Pneumonia (% of area)	19.50 (±12.48)	26.00 (±15.16)	0.3906**
Diffuse Alveolar Damage (% of area)	28.82 (±19.34)	43.75 (±16.85)	0.0742**
Pneumonitis (% of area)	23.52 (±17.33)	20.00 (±8.16)	0.5435**
Pulmonary infarction (% of area)	25.00 (±10.00)	10.00 (±0.00)	0.2235**
<b>Inflammasome activation</b>			
NLRP3 puncta per parenchyma area (mm <sup>2</sup> )	204.3 (±155.5)	204.0 (±156.6)	0.9310**
ASC puncta per parenchyma area (mm <sup>2</sup> )	251.8 (±192.5)	267.3 (±133.1)	0.4196**

\* Fisher's exact test

\*\* t-Test

# data after 18 days of hospitalization

846


847

848



849 **Figures and Figure Legends**

Fig. 1. Sá et al.




850

851 **Figure 1. Macrophages and endothelial cells contribute to inflammasome**  
 852 **activation in the lungs of COVID-19 patients.** Multiphoton microscopy  
 853 analysis of lung autopsies of 47 COVID-19 patients and 5 uninfected controls  
 854 (benign area of the lungs from adenocarcinoma patients). Images of ASC (**A-D**)  
 855 or NLRP3 (**E-H**) puncta (red, indicated by white arrows) in CD64<sup>+</sup> (in green; **A**,  
 856 **E**), CD34<sup>+</sup> (in purple; **B**, **F**), PDPN<sup>+</sup> (in green; **C**, **G**) and SFTPC<sup>+</sup> (in green; **D**,  
 857 **H**) cells from a lung autopsy of a COVID-19 patient. DAPI stains cell nuclei

858 (blue). Scale bars 10  $\mu\text{m}$ . The images were acquired by multiphoton microscopy  
859 using a 63x oil immersion objective and analyzed using ImageJ Software. (I-P)  
860 percentage of macrophages ( $\text{CD64}^+$ ), endothelial cells ( $\text{CD34}^+$ ), type I  
861 pneumocytes ( $\text{PDPN}^+$ ), and type II pneumocytes ( $\text{SFTPC}^+$ ) containing ASC (I-  
862 L) or NLRP3 (M-P) puncta. Each dot in the figures represents the value  
863 obtained from each individual. P-values are described in the figures comparing  
864 the indicated groups, as determined by Mann–Whitney test. Data are  
865 represented as violin plots with median and quartiles.

866


Fig. 2. Sá et al.



867

868 **Figure 2. Inflammasome activation positively correlates with disease time,**  
869 **and viral load inversely correlates with disease time. Spearman correlation**  
870 **of pulmonary viral load, inflammasome activation and illness time in 47 fatal**

871 COVID-19 patients. (A) Correlation of viral N2 with illness time; (B) Correlation  
 872 of viral E with illness time; (C) Correlation of NLRP3 puncta per parenchyma  
 873 area with illness time; (D) Correlation of ASC puncta per parenchyma area with  
 874 illness time; (E) Correlation of NLRP3 puncta per parenchyma area with  
 875 PaO<sub>2</sub>/FiO<sub>2</sub>. r and P-values are indicated in the figures.  
 876




877

878 **Figure 3. Pulmonary viral load and inflammatory gene expression define**  
 879 **two patient clusters in lethal cases of COVID-19.** (A) Heatmap of the mRNA  
 880 expression of inflammasomes, inflammatory molecules/cytokines and viral N2  
 881 and E in lung autopsies of 47 COVID-19 patients. PaO<sub>2</sub>/FiO<sub>2</sub> (B) and A-a O<sub>2</sub>  
 882 gradient (C) during disease development of patients from Cluster 1 (N=16,  
 883 green) and Cluster 2 (N=31, red). \*, P < 0.05 comparing the indicated groups,  
 884 as determined by Area Under Curve test. (D-H) Analysis of Cluster 1 and  
 885 Cluster 2 for illness time (D), PaO<sub>2</sub>/FiO<sub>2</sub> (E), A-a O<sub>2</sub> gradient (F), fibrosis (G),

886 and NLRP3 puncta per lung parenchyma area (H). Each dot in the figure  
887 represents the value obtained from each individual. P-values are described in  
888 the figures comparing the indicated groups, as determined by Mann–Whitney  
889 test. Data are represented as violin plots with median and quartiles. (I–J)  
890 Representative H&E images of lung parenchyma of 3 patients of cluster 1 (I)  
891 and 3 patients of cluster 2 (J). Scale bars 200  $\mu$ m.

892




893

894 **Figure 4. COVID-19 patients from Cluster 1 contain higher viral loads in**  
895 **the lungs than patients from Cluster 2. Quantification of viral N2 (A) and E**  
896 **(B) in lung autopsies of 47 COVID-19 patients from Cluster 1 (N=16) and**

897 Cluster 2 (N=31). **(C)** Quantification of the percentage of area stained for viral  
898 Spike protein in lung autopsies. Each dot in the figure represents the value  
899 obtained from each individual. P-values are described in the figures comparing  
900 the indicated groups, as determined by Mann–Whitney test. Data are  
901 represented as violin plots with median and quartiles. **(D-E)** Representative  
902 images of lung tissues stained for Spike (red) and Hematoxylin (blue). Scale  
903 bars 100  $\mu\text{m}$ .



Fig.5. Sá et al.



904

905 **Figure 5. Fibrosis is increased in cluster 2 patients.** (A-B) Histopathological  
 906 analysis of pulmonary samples from Cluster 1 and Cluster 2 for the presence of  
 907 fibrosis (A) and Disseminated Intravascular Coagulation (B). (C) Platelet counts  
 908 by laboratory analyses of blood samples from COVID-19 patients on the last

909 day of hospitalization. **(D)** Volcano plot analysis showing expression of fibrosis-  
 910 related genes in lung autopsy of COVID-19 patients. Each dot in this figure  
 911 represents a gene (average gene expression of 47 patient samples). Fold  
 912 change Cluster 2/Cluster 1). The genes with statistically significant differences  
 913 are indicated in color dots: *Plg* **(E)**, *Plat* **(F)**, *Plau* **(G)**, *Ccr2* **(H)**, *Ccl3* **(I)**, *Cdkna1*  
 914 **(J)**, *Serpina1* **(K)**, *Timp2* **(L)**, and *Fgf1* **(M)**. Each dot in the figures **(A, C, E-M)**  
 915 represents the value obtained from each individual. P-values are described in  
 916 the figures comparing the indicated groups, as determined by Mann–Whitney  
 917 test. Data are represented as violin plots with median and quartiles. **(N-O)**  
 918 Representative images of Masson-Goldner staining of lung parenchyma from  
 919 three Cluster 1 patients **(N)** and three Cluster 2 patients **(O)**. Shown are Nuclei  
 920 (dark brown to black), Collagen (green/blue), Erythrocytes (bright red). Scale  
 921 bars 200µm.

## 922 **Supplementary Table 1.**


**Supplementary Table 1.** The list of primer sequences for real time-PCR

Gene	Sequence of primer (5'- 3')
Human <i>Nlrp3</i>	F: GGAAGTGAAGCACCTGTTGTGCA R: TCCTGAGTCTCCCAAGGCATTC
Human <i>Il1a</i>	F: TGTATGTGACTGCCCAAGATGAAG R: AGAGGAGGTGGTCTCACTACC
Human <i>Il1ra</i>	F: ATGGAGGGAAGATGTGCCTGTG R: GTCCTGCTTTCTGTTCTCGCTC
Human <i>Nlr4</i>	F: AGGTCCACAACTCGTCAAGCT R: TGCTCACACGATTTCCTGCCAA
Human <i>Pycard</i>	F: AGCTCACCGCTAACGTGCTGC R: GCTTGGCTGCCGACTGAGGAG
Human <i>Nlrp1</i>	F: ATTGAGGGCAGGCAGCACAGAT R: CTCCTCAGGTTTCTGGTGACC
Human <i>Casp1</i>	F: GCTGAGGTTGACATCACAGGCA R: TGCTGTGAGGTTCTGTGCTC
Human <i>Aim2</i>	F: GCTGCACCAAAAGTCTCTCCTC R: CTGCTTGCCTTCTGGGTCTCA
Human <i>Il6</i>	F: AGACAGCCACTCACCTTTCAG R: TTCTGCCAGTGCCTCTTTGCTG
Human <i>Gapdh</i>	F: GTCTCCTCTGACTTCAACAGCG R: ACCACCCTGTTGCTGTAGCCAA
Human <i>Tnf Alpha</i>	F: CTCTTCTGCCTGCTGCCTTTG R: ATGGGCTACAGGCTTGTCACTC
Human <i>Il10</i>	F: TCTCCGAGATGCCTTCAGCAGA R: TCAGACAAGGCTTGGCAACCCA
Human <i>Il1b</i>	F: CCACAGACCTTCCAGGAGAATG R: GTGCAGTTCAGTGATCGTACAGG
Human <i>Il18</i>	F: GATAGCCAGCCTAGAGGTATGG R: CCTTGATGTTATCAGGAGGATTCA
Human <i>Casp4</i>	F: GGGATGAAGGAGCTACTTGAGG R: CCAAGAATGTGCTGTGAGGAGC
Human <i>Il17a</i>	F: CGGACTGTGATGGTCAACCTGA R: GCACTTTCCTCCAGATCACA
Human <i>Ifng</i>	F: GAGTGTGGAGACCATCAAGGAAG R: TGCTTTGCGTTGGACATTCAAGTC
Human <i>Ifnb1</i>	F: CTTGGATTCTACAAAGAAGCAGC R: TCCTCCTTCTGGAAGTCTGCTCA
Human <i>Ifna1</i>	F: AGAAGGCTCCAGCCATCTCTGF R: TGCTGGTAGAGTTCGGTGCAGA
Human <i>Il4</i>	F: CCGTAAACAGACATCTTGTGCTCC R: GAGTGTCTTCTCATGGTGGCT

923

924 **Supplementary Figures and Supplementary Figure Legends**

Supplementary Fig. 1. Sá et al.



925


926 **Supplementary Fig. 1. Histopathological patterns and inflammasome**  
 927 **activation in lung autopsy of COVID-19 patients.** Histopathological analysis  
 928 of lethal cases of COVID-19 patients. (A) Proportion of lung parenchyma area  
 929 (loss of airspace) of COVID-19 patients and uninfected controls (benign area of  
 930 the lungs from adenocarcinoma patients). (B-C) Representative images of H&E  
 931 stain showing the lung parenchyma. Scale bars 200  $\mu$ m. (D-G) Multiphoton  
 932 microscopy analysis of lung autopsies of 47 COVID-19 patients and 5



933 uninfected controls. Tissues were stained with anti-ASC (**D, E**) or anti-NLRP3  
934 (**F, G**) for quantification of cells with inflammasome puncta in lung autopsies (in  
935 red, indicated by white arrows). DAPI stains cell nuclei (blue). Insets indicate a  
936 higher magnification of the indicated region (red rectangle). Scale bars 20  $\mu\text{m}$ .  
937 (**H**) Percentage of NLRP3 puncta colocalizing with ASC puncta in the lungs of  
938 five COVID-19 patients. (**I**) Representative images showing ASC (green) and  
939 NLRP3 (red) colocalization. Scale bar 10  $\mu\text{m}$ . Each dot in the figure represents  
940 the value obtained from each individual. P-values are shown in the figures  
941 comparing the indicated groups, as determined by Mann–Whitney test. Data are  
942 represented as violin plots with median and quartiles. The images were  
943 acquired by multiphoton microscope using a 63x oil immersion objective and  
944 analyzed using ImageJ Software.

945

Supplementary Fig. 2. Sá et al.




946

947 **Supplementary Fig. 2. Total numbers of macrophages, endothelial cells,**  
948 **and type I and II pneumocytes are similar in the lungs of COVID-19**  
949 **patients and uninfected controls.** Multiphoton microscopy analysis of lung  
950 autopsies of 47 COVID-19 patients and 5 uninfected controls (benign area of  
951 the lungs from adenocarcinoma patients). (**A-D**) Numbers of macrophages  
952 ( $\text{CD64}^+$ , **A**), endothelial cells ( $\text{CD34}^+$ , **B**), type I pneumocytes ( $\text{PDPN}^+$ , **C**) and  
953 type II pneumocytes ( $\text{SFTPC}^+$ , **D**) per lung parenchyma area. Each dot in the  
954 figures represents the value obtained from each individual. P-values are shown  
955 in the figures comparing the indicated groups, as determined by Mann–Whitney  
956 test. Data are represented as violin plots with median and quartiles.

957

Supplementary Fig. 3. Sá et al.




958

959 **Supplementary Fig. 3. Immunohistochemistry analysis of lung autopsies**  
 960 **of patients with COVID-19 and uninfected controls.** Immunohistochemistry  
 961 analysis of lung autopsies of 47 COVID-19 patients and 5 uninfected controls  
 962 (benign area of the lungs from adenocarcinoma patients). Quantification of the  
 963 percentage of area stained for ASC (**A**), NLRP3 (**B**), cleaved GSDMD (**C**), IL-1 $\beta$   
 964 (**D**) and Caspase-1 (**E**). Each dot in the figures represents the value obtained  
 965 from each individual. P-values are shown in the figures comparing the indicated  
 966 groups, as determined by Mann–Whitney test. Data are represented as violin  
 967 plots with median and quartiles. (**F-H**) Representative images of lungs from fatal  
 968 cases of COVID-19, indicating colocalization of viral Spike, ASC, NLRP3,  
 969 Caspase-1, IL-1 $\beta$  and cleaved GSDMD in endothelial cells (CD34<sup>+</sup>, **F**),  
 970 macrophages (CD68<sup>+</sup>, **G**), and type II pneumocytes (SFTPC<sup>+</sup>, **H**).

971

Supplementary Fig. 4. Sá et al.




972

973 **Supplementary Fig. 4. Non-significant correlation or viral loads and**  
974 **inflammasome activation in lethal cases of COVID-19 patients.** Spearman  
975 correlation of pulmonary viral load and inflammasome activation in 47 fatal  
976 COVID-19 patients. **(A)** Correlation of viral N2 with NLRP3 puncta per  
977 parenchyma area; **(B)** Correlation of viral E with NLRP3 puncta per parenchyma  
978 area; **(C)** Correlation of viral N2 with ASC puncta per parenchyma area; **(D)**  
979 Correlation of viral E with ASC puncta per parenchyma area.  $r$  and  $p$ -value are  
980 indicated in the figure.

981

Supplementary Fig. 5. Sá et al.




982

983 **Supplementary Fig. 5. Gene expression in lungs of COVID-19 patients.**

984 Correlation matrix of inflammasome and inflammatory gene expression in lung  
 985 autopsy of 47 COVID-19 patients (A). Colors indicate correlation scores,  
 986 categorized as positive strong control ( $r \geq 0.70$ ; red); moderate positive  
 987 correlation ( $0.50 \geq r \leq 0.70$ ; orange); weak positive correlation ( $0.30 \geq r \leq 0.50$ ;  
 988 yellow); negative strong correlation ( $r \geq -0.70$ ; dark blue); negative moderate  
 989 correlation ( $-0.50 \geq r \leq -0.70$ ; blue) or negative weak correlation ( $-0.30 \geq r \leq$   
 990  $0.50$ ; light blue). Only correlations with  $p < 0.05$  are represented in the correlation  
 991 matrix. (B-U) Expression of mRNA in the lung autopsies of COVID-19 patients  
 992 and uninfected controls (benign area of the lungs from adenocarcinoma  
 993 patients). Selected genes were *Il6* (B), *Il10* (C), *Il17* (D), *Ifna1* (E), *Ifnb1* (F), *Ifng*  
 994 (G), *Il4* (H), *Il2* (I), *Tnfa* (J), *Il1a* (K), *Il1b* (L), *Il18* (M), *I1ra* (N), *Nlrp3* (O), *Nlrp4*  
 995 (P), *Nlrp1* (Q), *Aim2* (R), *Pycard* (S), *Casp1* (T), *Casp4* (U).

996

Supplementary Fig. 6. Sá et al.



997

998 **Supplementary Fig. 6. CXR evolution of patients from Cluster 1 and**  
 999 **Cluster 2.** Analysis of the first and last Chest x-radiography (CXR) of 47  
 1000 COVID-19 patients belonging from Cluster 1 (n=15) and Cluster 2 (n=31). **(A)**  
 1001 patients with reduced opacities (green), stability (blue) and increased opacities  
 1002 (red) comparing the first and last CXR. Impaired analyses are shown in gray.  
 1003 Representative images of first and last CXR from two patients from Cluster 1,  
 1004 indicating stability in moderate and mild pneumonia **(B)** and two patients from  
 1005 Cluster 2, indicating worsening conditions in cases of severe pneumonia **(C)**.